相关临床试验
99
16 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1956
进行中（未招募）
4
4.0%
已完成
51
51.5%
Enrolling By Invitation
1
1.0%
尚未招募
11
11.1%
招募中
13
13.1%
暂停
1
1.0%
终止
3
3.0%
Unknown
13
13.1%
撤回
2
2.0%
暂无批准数据
- Reanalysis of a 52-week international clinical trial of over 300 PSP patients found that Davunetide significantly slowed disease progression in women but not men. - Treated women preserved key daily functions including balance, fine motor skills, and cognitive abilities such as memory and language. - Researchers discovered profound molecular differences between sexes, with tau pathology–symptom relationships reversed in women versus men. - Findings underscore the necessity of sex-specific analysis in neurodegenerative disease trials and may inform future Alzheimer's research.
- Tel Aviv University researchers discovered a rare subset of cochlear supporting cells, termed transdifferentiating Deiters' cells (tDCs), capable of converting into sensory hair cells upon Notch pathway inhibition. - The study, published in Science Advances, used live tissue imaging and single-cell multi-omics to reveal that only a distinct subpopulation of supporting cells possesses this regenerative potential, not all supporting cells uniformly. - Inhibiting the Notch signaling pathway triggered these tDCs to enter a transitional state and begin transforming into hair cells, a process previously thought impossible in mature mammals. - Researchers caution the work remains basic research, with significant hurdles in regulation, cost, and expanding regenerative capacity to additional cells before clinical translation can occur.
- AI is forcing medical schools to rapidly reconsider physician training, with educators describing this as a "key inflection point for medical education," according to NYU's Marc Triola. - New AI tools enable personalized assessment of trainees' communication and clinical reasoning skills, areas that have long been difficult to evaluate directly. - Concerns about "never-skilling" and "deskilling" arise as trainees offload cognitive tasks to AI, though some experts argue not all deskilling is harmful and may free capacity for essential skills. - Medical education leaders emphasize the need for adaptive training models that partner with learners, as the evidence base on AI's educational effects remains surprisingly limited.
- A new study in Genomic Psychiatry shows that estrogen levels during the estrous cycle significantly affect how much intranasal davunetide reaches the brain in mice, with peak uptake during high-estrogen phases. - Reanalysis of human pharmacokinetic data found women reached roughly twice the peak drug concentrations of men, while men retained the drug longer, suggesting sex-based differences in drug exposure. - The findings may explain why a large Phase 2/3 trial of davunetide in progressive supranuclear palsy failed to show overall benefit, as sex-stratified analyses hinted women responded when men did not. - Researchers caution that sex and hormonal status may need to be considered when designing animal studies, clinical trials, and dosing strategies for brain-directed intranasal therapies.
- NeuroThera Labs, a SciSparc subsidiary focused on CNS disorders, signed a definitive agreement to acquire 54.01% of CliniQuantum for approximately $9.46 million in stock consideration. - CliniQuantum develops quantum computing platforms to transform clinical trials by analyzing complex datasets for smarter, faster, and more adaptive study designs. - The acquisition includes potential earn-out payments up to $2.5 million based on patent filings and fundraising milestones over a three-year period. - The transaction is expected to close around March 31, 2026, pending Israeli tax authority approval and other closing conditions.
- Tel Aviv University researchers identified a previously unknown molecular mechanism driving ALS progression involving reduced microRNA-126 levels and toxic TDP-43 protein aggregates. - RNA-based gene therapy using microRNA-126 successfully stopped nerve cell degeneration and promoted regeneration in human cells and animal models. - The breakthrough findings reveal that muscle cells normally produce microRNA-126 to regulate TDP-43 protein expression at neuromuscular junctions. - This discovery could serve as the foundation for developing effective treatments for ALS, a fatal neurodegenerative disease affecting millions worldwide.
- NurExone's ExoPTEN therapy demonstrated 100% recovery of walking ability in animals with spinal cord injuries when treated with higher doses, compared to only 1 out of 6 untreated animals achieving this milestone. - Preclinical studies for glaucoma treatment showed dose-dependent therapeutic effects, with high-dose ExoPTEN achieving response amplitudes comparable to uninjured eyes in optic nerve injury models. - The company plans to initiate Phase 1/2a clinical trials for acute spinal cord injuries in 2026, targeting adult patients with traumatic injuries between spinal levels C5 and T10. - ExoPTEN has received Orphan Drug Designation from both the FDA and European Medicines Agency, providing market exclusivity and development incentives.
- Researchers developed a novel monoclonal antibody (αFZD7-288.1) that specifically targets the Frizzled 7 receptor and significantly inhibits Wilms tumor growth in preclinical studies. - The antibody disrupts canonical Wnt signaling by reducing active β-catenin levels and downregulating key target genes including C-MYC, AXIN2, and CCND1. - In vivo xenograft studies demonstrated that αFZD7-288.1 treatment at 10 mg/kg significantly reduced tumor volumes with minimal toxicity compared to paclitaxel chemotherapy. - The treatment effectively reduced cancer stem cell markers including NCAM1, SIX2, CITED1, and ALDH1, suggesting potential to overcome treatment resistance.
- Researchers at Sheba Medical Center and Tel Aviv University have successfully grown human fetal kidney components from tissue stem cells for up to 34 weeks, marking the first time such organoids have survived beyond four weeks in laboratory conditions. - The breakthrough enables scientists to study congenital kidney defects in real-time, test drug toxicity during pregnancy, and develop new treatments using human-like models instead of relying solely on mouse studies. - The team is now seeking funding, including from China, to advance the technology toward clinical trials, with hopes of developing regenerative therapies that could repair damaged kidneys and reduce transplant needs.
- NeuroSense Therapeutics' PrimeC demonstrated a statistically significant 33% reduction in ALS disease progression (p=0.007) and 58% improvement in survival rates in its Phase 2b PARADIGM trial. - The oral combination therapy showed differential expression of over 100 microRNAs, including downregulation of miR-199 and miR-181 associated with neuroinflammation and mortality. - Despite promising clinical results, the company faces financial constraints with only $3.4 million in cash and is pursuing a critical partnership to fund Phase 3 trials beginning in late 2025.
